Pediatric Obesity Pharmacotherapy Selector

---
name: pediatric-obesity-pharmacotherapy-selector
description: Select the right pharmacologic agent for a child aged 12+ with obesity using the CMAJ 2025 guideline — choosing between GLP-1 receptor agonists, metformin, or orlistat with monitoring guidance. Trigger when a clinician asks which medication to use for pediatric obesity, whether to start semaglutide or metformin in a child, or how to manage obesity pharmacologically in adolescents.
---

# Pediatric Obesity: Pharmacotherapy Selector

Step-by-step guide to selecting and initiating pharmacotherapy in children ≥12 years with obesity. All agents must be combined with behavioural and psychological interventions.

Based on CMAJ 2025 Clinical Practice Guideline (Ball et al., doi: 10.1503/cmaj.241456).

---

## Step 1 — Confirm Eligibility

Before prescribing, confirm all three:

| Check | Criteria |
|---|---|
| Age | ≥ 12 years (no evidence for < 12) |
| Diagnosis | Obesity confirmed (BMIz using WHO/Canadian charts) |
| Behavioural program | Currently enrolled or starting alongside medication |

> ⚠️ **Pharmacotherapy must always be co-prescribed with behavioural and psychological interventions.** Medication alone is not recommended.

---

## Step 2 — Assess Contraindications and Preferences

Before selecting an agent, screen for:

- **GI conditions** (IBD, gastroparesis) — caution with GLP-1RAs
- **Eating disorder** (binge eating, atypical anorexia) — psychiatric clearance before any pharmacotherapy
- **Renal or hepatic impairment** — affects metformin dosing
- **Family access and affordability** — GLP-1RAs are costly; metformin widely available
- **Patient/family values** — injection vs. oral, frequency, side effect tolerability

---

## Step 3 — Select Agent

### Option A — GLP-1 Receptor Agonists (Preferred where accessible)
*Semaglutide, liraglutide, exenatide*
**Conditional recommendation; very low to low certainty**

**Best for:** Significant BMIz reduction needed; cardiometabolic comorbidities (hypertension, dyslipidaemia, insulin resistance)

**Evidence:**
- BMIz: small to large reduction (semaglutide has largest effect — very large effect on BMIz; 1 RCT, 201 children aged 12–17)
- HRQoL: small benefit (semaglutide); little/no effect for others
- Triglycerides: large benefit (semaglutide); small for others
- HDL-C, LDL-C, total cholesterol, systolic BP: small benefit (semaglutide)

**Common AEs (important — discuss upfront):**
- GI: nausea, diarrhea, vomiting, abdominal pain (most common; 79% semaglutide vs. 82% placebo — many are trivial and self-limiting)

**Serious AEs (uncertain risk):**
- Cholelithiasis, appendicitis (11% semaglutide vs. 9% placebo in key RCT)
- Risk appears similar to control groups but uncertain — monitor

**Semaglutide note:** Stronger evidence than liraglutide/exenatide based on current data, but guideline recommends GLP-1RAs as a class due to limited paediatric RCTs.

---

### Option B — Biguanides (Metformin)
*Good first option, especially if GLP-1RAs unavailable or unaffordable*
**Conditional recommendation; low to moderate certainty**

**Best for:** Insulin resistance present; oral route preferred; cost/access barrier to GLP-1RAs

**Evidence:**
- BMIz: moderate reduction
- Cardiometabolic: small benefits on lipids and insulin resistance
- HRQoL, anxiety, depression: little to no effect

**AEs:**
- No serious AEs reported in paediatric studies
- Mild-moderate GI (nausea, diarrhea) — more than placebo but manageable; start low and titrate
- Not associated with increased serious AEs (critical safety advantage over GLP-1RAs)

---

### Option C — Lipase Inhibitors (Orlistat)
*Use only if A and B are unavailable or contraindicated*
**Conditional recommendation; low certainty — least preferred**

**Evidence:** Lacks evidence on HRQoL, depression, anxiety.

**AEs:**
- More serious AEs than control (critically important — higher risk)
- More mild-moderate GI AEs (oily stools, faecal urgency, leakage)
- Fat-soluble vitamin malabsorption — supplement required

> ⚠️ **Avoid as first choice.** Only use if GLP-1RAs and metformin are not feasible.

---

## Step 4 — Initiate and Counsel

Before prescribing, cover all three with the child and family:

1. **Expected benefits:** BMIz reduction is likely modest in most (not guaranteed); improvements in cardiometabolic markers; possibly HRQoL
2. **Expected harms:** Discuss the relevant AE profile for the chosen agent
3. **Duration:** Obesity is chronic — medication may be long-term; reassess regularly
4. **What to do if GI side effects occur:** Reassure most are transient; hydration; dose titration strategy

---

## Step 5 — Monitoring Plan

Review at **3 months**, then every **6 months**:

| Outcome | Why |
|---|---|
| BMIz | Primary efficacy marker |
| HRQoL (PedsQL or similar) | Critically important to families |
| Depression & anxiety screening | Critically important — monitor throughout |
| BP (systolic and diastolic) | Cardiometabolic target |
| Fasting lipids (total cholesterol, LDL-C, HDL-C, TG) | Cardiometabolic benefit expected |
| Fasting insulin / HOMA-IR | Insulin resistance marker |
| ALT | Hepatic safety (especially GLP-1RAs) |
| GI adverse events | Adherence-limiting; especially GLP-1RAs |
| Serious AEs (hospitalisation) | Especially cholelithiasis with GLP-1RAs |

---

## Clinical Guardrails

- **No pharmacotherapy under 12 years** — no evidence base; do not extrapolate
- **Always combine with behavioural program** — medication alone is not guideline-concordant
- **Screen for eating disorders before starting** — pharmacotherapy may worsen body image disturbance
- **Shared decision-making is mandatory** — especially given low-to-moderate certainty evidence for all agents
- **Discontinue if no benefit after adequate trial** (typically 3–6 months) and reassess
- **GLP-1RAs are not stepwise** — can be offered alongside or before trying metformin based on clinical picture and family preference

---

## Source

CMAJ 2025 Clinical Practice Guideline: *Managing obesity in children.*
Ball GDC et al. CMAJ 2025 April 14; 197:E372–89. doi: [10.1503/cmaj.241456](https://doi.org/10.1503/cmaj.241456)
Updated version: June 3, 2025.